

| | |
|-------------------------|---|
| NCT ID | NCT04599140 |
| Title | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial |
| Phase | Phase 1 |
| Date Added | 2020-10-22 |
| Location | Texas, United States |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | Recruiting |
| Drugs | CXCR1/2 Inhibitor SX-682, Nivolumab |
| Tags | MSS/ MMRp |
| NCT ID | NCT04724239 |
| Title | A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma |
| Phase | Phase 2 |
| Date Added | 2021-01-26 |
| Location | China |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | Active, not recruiting |
| Drugs | chidamide, IBI305, Sintilimab |
| Tags | MSS/ MMRp |
| NCT ID | NCT06566755 |
| Title | Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer |
| Phase | Phase 3 |
| Date Added | 2024-08-22 |
| Location | China |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | Recruiting |
| Drugs | |
| Tags | MSS/ MMRp |
| NCT ID | NCT06589440 |
| Title | Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) |
| Phase | Phase 2 |
| Date Added | 2024-09-19 |
| Location | New Jersey, United States Texas, United States Washington, United States |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | Recruiting |
| Drugs | Balstilimab, Botensilimab |
| Tags | MSS/ MMRp |
| NCT ID | NCT06493760 |
| Title | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients |

| | |
|------------------|---|
| Phase | Phase 2 |
| Date Added | 2024-07-10 |
| Location | China |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | Recruiting |
| Drugs | |
| Tags | MSI-H/ MMRd, MSS/ MMRp |
| NCT ID | NCT06513221 |
| Title | A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab |
| Phase | |
| Date Added | 2024-07-22 |
| Location | |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | |
| Drugs | |
| Tags | MSS/ MMRp |
| NCT ID | NCT06788171 |
| Title | PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM |
| Phase | Phase 2 |
| Date Added | 2025-03-25 |
| Location | China |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | Not yet recruiting |
| Drugs | |
| Tags | MSS/ MMRp |
| NCT ID | NCT06794086 |
| Title | SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases |
| Phase | Phase 3 |
| Date Added | 2025-01-27 |
| Location | China |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | Recruiting |
| Drugs | |
| Tags | MSS/ MMRp |
| NCT ID | NCT06792695 |
| Title | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer |
| Phase | Phase 2 |
| Date Added | 2025-03-25 |

| | |
|-------------------------|---|
| Location | Arizona, United States |
| | California, United States |
| | District of Columbia, United States |
| | Illinois, United States |
| | Maryland, United States |
| | Massachusetts, United States |
| | Minnesota, United States |
| | New York, United States |
| | Ohio, United States |
| | Texas, United States |
| | Australia |
| | Canada |
| | China |
| | France |
| | Germany |
| | Italy |
| | Korea, Republic of |
| | Spain |
| | Taiwan |
| | United Kingdom |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | Recruiting |
| Drugs | |
| Tags | MSS/ MMRp |
| <hr/> | |
| NCT ID | NCT06801665 |
| Title | FMT+ QL1706+bevacizumab+ XELOX As First-line Treatment for Advanced MSS-type Colon Cancer with Liver Metastasis |
| Phase | Phase 2 |
| Date Added | 2025-01-30 |
| Location | |
| Prior IO Allowed | No |
| CRC-directed | Yes |
| Status | Not yet recruiting |
| Drugs | |
| Tags | MSS/ MMRp |